Loss of heterozygosity and absence of MAX immunostaining in a prolactinoma associated with multiple endocrine neoplasia type 5 (MEN5).

Fiche publication

Date publication

novembre 2025

Journal

Pituitary

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOULAGNON-ROMBI Camille

Tous les auteurs :
Delemer B, Florea SM, Decoudier B, Boulagnon-Rombi C, Karna B, Pellegata NS, Buffet A, Beckers A, Pétrossians P, Daly AF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41222780

Résumé

Multiple endocrine neoplasia type 5 (MEN5) is an emerging syndrome caused by germline pathogenic variants involving the MYC Associated Factor X (MAX) gene. Affected individuals typically have pheochromocytomas, often bilateral, at a relatively early age. In MAX pheochromocytoma cohorts, pituitary adenomas are rarely reported. The role of MAX as a tumor suppressor gene in the pituitary gland has not been directly proven to date.